Zai Lab Ltd (ZLAB):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Zai Lab Ltd (ZLAB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8119
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Zai Lab Ltd (Zai Lab) is a biopharmaceutical company that discovers, develops and manufactures transformative medicines for cancer, autoimmune and infectious diseases. The company’s pipeline products include ZL-2306, ZL-2401, FPA144, EXT2514SUL, ZL-2301, ZL-3101, ZL-2302 and ZL-1101. It develops drugs for treatment of ovarian cancer and breast cancer in Phase II stage, lung cancer in Phase II stage, infectious diseases in phase III stage, and eczema and psoriasis in phase II stage, among others. Zai Lab’s FPA144 is used for the treatment of gastric cancer and EXT2514SUL is used for acinetobacter baumannii. The company operates its offices in Pudong, Beijing and Suzhou, China. Zai Lab is headquartered in Pudong, China.

Zai Lab Ltd (ZLAB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zai Lab Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Zai Lab Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
ZAI Lab Raises USD30 Million in Series C Financing 12
dMed Raises USD8 Million in Series A Financing 13
ZAI Labs Raises More Than USD100 Million in Series B Financing 14
ZAI Labs Raises More Than USD30 Million in Series A Venture Financing 15
Partnerships 17
Zai Lab Enters into Licensing Agreement with Paratek Pharma 17
GE Healthcare and Zai Lab Enter into Agreement 18
Zai Lab (Shanghai) Enters into Partnership with Tsinghua University Immunology Institute 19
Licensing Agreements 20
Zai Lab Enters into Licensing Agreement with Novocure 20
Zai Lab Enters into Licensing Agreement with Crescendo Biologics 22
Zai Lab Enters into Licensing Agreement with Entasis Therapeutics 23
Zai Lab Enters into Licensing Agreement with Five Prime Therapeutics 24
Zai Lab Enters into Licensing agreement with GlaxoSmithKline 25
Zai Lab Enters into Licensing Agreement with Tesaro 26
Zai Lab Enters into Licensing Agreement with Hanmi Pharma 27
Zai Lab Enters into Licensing Agreement with UCB 28
Zai Lab Enters into Licensing Agreement with Sanofi 29
Zai Lab Enters Into Licensing Agreement With Bristol-Myers Squibb 30
ZAI Lab Enters into Licensing Agreement with Sanofi for Two Respiratory Drugs 31
Equity Offering 32
Zai Lab Prices Public Offering of ADS for USD150 Million 32
Zai Lab Raises USD172.5 Million in IPO 34
Zai Lab Ltd – Key Competitors 36
Zai Lab Ltd – Key Employees 37
Zai Lab Ltd – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Corporate Communications 39
Aug 14, 2018: Zai Lab names professor Kai-Xian Chen, Ph.D., as Board Director 39
Jun 05, 2018: Zai Lab Expands Commercial Leadership Team, Appoints William Liang as Chief Commercial Officer 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Zai Lab Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zai Lab Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zai Lab Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Zai Lab Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ZAI Lab Raises USD30 Million in Series C Financing 12
dMed Raises USD8 Million in Series A Financing 13
ZAI Labs Raises More Than USD100 Million in Series B Financing 14
ZAI Labs Raises More Than USD30 Million in Series A Venture Financing 15
Zai Lab Enters into Licensing Agreement with Paratek Pharma 17
GE Healthcare and Zai Lab Enter into Agreement 18
Zai Lab (Shanghai) Enters into Partnership with Tsinghua University Immunology Institute 19
Zai Lab Enters into Licensing Agreement with Novocure 20
Zai Lab Enters into Licensing Agreement with Crescendo Biologics 22
Zai Lab Enters into Licensing Agreement with Entasis Therapeutics 23
Zai Lab Enters into Licensing Agreement with Five Prime Therapeutics 24
Zai Lab Enters into Licensing agreement with GlaxoSmithKline 25
Zai Lab Enters into Licensing Agreement with Tesaro 26
Zai Lab Enters into Licensing Agreement with Hanmi Pharma 27
Zai Lab Enters into Licensing Agreement with UCB 28
Zai Lab Enters into Licensing Agreement with Sanofi 29
Zai Lab Enters Into Licensing Agreement With Bristol-Myers Squibb 30
ZAI Lab Enters into Licensing Agreement with Sanofi for Two Respiratory Drugs 31
Zai Lab Prices Public Offering of ADS for USD150 Million 32
Zai Lab Raises USD172.5 Million in IPO 34
Zai Lab Ltd, Key Competitors 36
Zai Lab Ltd, Key Employees 37
Zai Lab Ltd, Other Locations 38

List of Figures
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Zai Lab Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Zai Lab Ltd (ZLAB):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Eloxx Pharmaceuticals Inc:企業のM&A・事業提携・投資動向
    Eloxx Pharmaceuticals Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Eloxx Pharmaceuticals Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • GliaCure Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary GliaCure Inc (GliaCure) is a developer of novel therapies for neurological and neuropsychiatric disorders. The company uses glia as an untapped resource for drug discovery, which controls the brain function in health and disease. It develops small molecule pharmaceuticals for the treatment o …
  • China Oriental Group Company Limited:企業の戦略・SWOT・財務情報
    China Oriental Group Company Limited - Strategy, SWOT and Corporate Finance Report Summary China Oriental Group Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Monadelphous Group Ltd (MND):企業の財務・戦略的SWOT分析
    Monadelphous Group Ltd (MND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Sparton Resources Inc (SRI):企業の財務・戦略的SWOT分析
    Summary Sparton Resources Inc (Sparton Resources) is a diversified company that acquires and develops oil and gas properties in North America and China. The company’s products include vanadium, natural gas, crude oil, gold, and vanadium flow batteries, among others. Its energy projects comprise Sier …
  • United States Postal Service:企業の戦略的SWOT分析
    United States Postal Service - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Ameriprise Financial, Inc. (AMP):企業の財務・戦略的SWOT分析
    Ameriprise Financial, Inc. (AMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • The New York Times Company (NYT):企業の財務・戦略的SWOT分析
    The New York Times Company (NYT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • McKinsey & Co Inc:企業の戦略的SWOT分析
    McKinsey & Co Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Zoll Medical Corporation:医療機器:M&Aディール及び事業提携情報
    Summary ZOLL Medical Corporation (Zoll), a subsidiary of Asahi Kasei Corporation, is a provider of medical devices and software solutions for advance emergency care. The company designs, manufactures and markets resuscitation devices and systems used for resuscitation and acute critical care victims …
  • Andhra Pradesh Power Generation Corp Ltd:企業の戦略的SWOT分析
    Andhra Pradesh Power Generation Corp Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • American Bridge Company:企業の戦略・SWOT・財務分析
    American Bridge Company - Strategy, SWOT and Corporate Finance Report Summary American Bridge Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Athena Investments AS (ATHENA):企業の財務・戦略的SWOT分析
    Athena Investments AS (ATHENA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Tribune Media Company:企業の戦略・SWOT・財務分析
    Tribune Media Company - Strategy, SWOT and Corporate Finance Report Summary Tribune Media Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Eastman Chemical Co (EMN):企業の財務・戦略的SWOT分析
    Eastman Chemical Co (EMN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Fiesta Mart LLC:企業の戦略的SWOT分析
    Fiesta Mart LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Mauna Kea Technologies SAS (MKEA):企業の財務・戦略的SWOT分析
    Summary Mauna Kea Technologies SAS (MKT) is an endomicroscopy device manufacturer. The company develops, manufactures and distributes tools to visualize and detect cellular abnormalities during endoscopic procedures. It provides confocal laser endomicroscopy platform. MKT’s cellvizio is an endomicro …
  • Royal Dutch Shell plc:企業のM&A・事業提携・投資動向
    Royal Dutch Shell plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Royal Dutch Shell plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Clearwater Seafoods Incorporated (CLR):企業の財務・戦略的SWOT分析
    Clearwater Seafoods Incorporated (CLR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • NanoViricides Inc (NNVC)-製薬・医療分野:企業M&A・提携分析
    Summary NanoViricides Inc (NanoViricides), formerly Edot-com.com Inc is a biopharmaceutical company that provides nanomedicine technology solutions. The company conducts research in the areas of medical science and pharmaceutical technology such as polymeric micelles, multi-specific multi-targeting, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆